Yantai Dongcheng Pharmaceutical: A Day in the Market
On Friday, 23 October 2026, the shares of Yantai Dongcheng Pharmaceutical Co., Ltd. (stock code 002675.SZ) closed unchanged, reflecting a 0 % movement over the 24‑hour trading period that concluded at 07:34 AM Central Europe. The stock was available for purchase at approximately CN¥ 13.27 on major exchanges, a figure that sits just above the simple moving average of the last 200 days (CN¥ 12.81).
Market Snapshot
- Current price: CN¥ 13.27
- Total supply: 824.6 million shares
- Market capitalization: CN¥ 10.8 billion
- Trading volume (last 24 h): CN¥ 101.4 million
- Price change since month‑end: +2.82 %
- 52‑week high: CN¥ 16.14 (recorded 12 November 2025)
- 52‑week low: CN¥ 12.05 (recorded 22 June 2026)
The flat performance today follows a modest up‑trend that began at the close of the previous month, suggesting that the market has found a new equilibrium at the current level. Investors should note that the share price is trading close to the 200‑day moving average, a technical indicator often used to gauge medium‑term momentum.
Peer Comparison
In the same 24‑hour window, several comparable listings also traded flat:
| Stock | Code | Current Price | Market Cap | P/E (or other ratio) |
|---|---|---|---|---|
| Gempharmatech | 688046.SS | CN¥ 26.88 | CN¥ 12 bn | 68 |
| Information Tech | 300229.SZ | CN¥ 12.94 | CN¥ 11.9 bn | – |
| Shanghai Innostar Bio‑tech | 688710.SS | CN¥ 81.81 | CN¥ 11.9 bn | – |
| Crystal Clear Electronic M | 300655.SZ | CN¥ 10.17 | CN¥ 11.9 bn | 92.03 |
| Jafron Biomedical | 300529.SZ | CN¥ 15.17 | CN¥ 11.9 bn | 22.56 |
The lack of movement across these peers underscores a broader market pause rather than company‑specific volatility. However, the price‑to‑earnings ratios of Gempharmatech and Crystal Clear Electronic M, both exceeding 90, contrast sharply with Yantai Dongcheng’s more modest valuation, which may appeal to investors seeking stability within the pharmaceutical sector.
Company Profile
Yantai Dongcheng Pharmaceutical Co., Ltd. is headquartered in Yantai, China, and operates across the spectrum of pharmaceutical science. Its core activities include research and development, production, marketing, and capital management in three principal domains:
- Biochemical Active Pharmaceutical Ingredients (APIs) – supplying key components for drug synthesis.
- Chemical Synthetic Drugs – developing small‑molecule therapeutics for a range of indications.
- Modern Chinese Medicine – integrating traditional formulations with contemporary research methods.
The company’s diversified portfolio positions it to capitalize on both global demand for conventional pharmaceuticals and the growing interest in evidence‑based Chinese medicine.
Outlook
With its share price comfortably above the 200‑day average yet still within the 52‑week trading range, Yantai Dongcheng Pharmaceutical appears poised for a period of consolidation. Analysts will likely monitor upcoming quarterly earnings releases and any announced research milestones to gauge whether the company can sustain its upward trajectory. For now, the flat trading day serves as a neutral backdrop, offering investors a pause to assess the company’s strategic direction and the broader market environment.